{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Y"],"funding":["Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","National Natural Science Foundation of China"],"pagination":["990894"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9521709"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["<h4>Background</h4>Fluoroquinolones (FQs) are the most important second-line anti-tuberculosis (anti-TB) drugs, primarily used for the treatment of multidrug- or rifampicin-resistant TB (MDR/RR-TB). However, FQs are also commonly used to treat other bacterial infections. There are few published data on the rates of FQ resistance among rifampicin-susceptible TB.<h4>Methods</h4>We used whole-genome sequencing (WGS) to determine the prevalence of FQ resistance among rifampicin-susceptible TB in a rural district of Shanghai. This was a population-based retrospective study of all culture-positive pulmonary TB patients diagnosed in the Chongming district of Shanghai, China during 2009-2018.<h4>Results</h4>The rate of FQ resistance was 8.4% (29/345) among TB, 6.2% (20/324) among rifampicin-suscep"],"journal":["Frontiers in public health"],"pubmed_title":["Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study."],"pmcid":["PMC9521709"],"funding_grant_id":["21DZ2202400","81872679"],"pubmed_authors":["Jiang Y","Li J","Yu C","Zhang Y","Pan Q","Shen X"],"additional_accession":[]},"is_claimable":false,"name":"Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study.","description":"<h4>Background</h4>Fluoroquinolones (FQs) are the most important second-line anti-tuberculosis (anti-TB) drugs, primarily used for the treatment of multidrug- or rifampicin-resistant TB (MDR/RR-TB). However, FQs are also commonly used to treat other bacterial infections. There are few published data on the rates of FQ resistance among rifampicin-susceptible TB.<h4>Methods</h4>We used whole-genome sequencing (WGS) to determine the prevalence of FQ resistance among rifampicin-susceptible TB in a rural district of Shanghai. This was a population-based retrospective study of all culture-positive pulmonary TB patients diagnosed in the Chongming district of Shanghai, China during 2009-2018.<h4>Results</h4>The rate of FQ resistance was 8.4% (29/345) among TB, 6.2% (20/324) among rifampicin-suscep","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-06-21T03:10:24.759Z","creation":"2025-02-19T03:24:13.384Z"},"accession":"S-EPMC9521709","cross_references":{"pubmed":["36187694"],"doi":["10.3389/fpubh.2022.990894"]}}